An article published in January 2015 in Diabetes, Obesity and Metabolism explored the pharmacodynamics and the benefits of Dapagliflozin and Canagliflozin in the fight against obesity and type 2 diabetes. This double-blind, randomized study involved both males and females between the ages of 18 and 55. All participants were deemed healthy and free of significant medical illness. The study explored the pharmacodynamic effects of Dapagliflozin and Canagliflozin at their highest comparable therapeutic doses. Dapagliflozin was dosed at 10 milligrams orally, one time per day and Canagliflozin was dosed at 300 milligrams orally, also one time daily. Study participants received one of these highly effectual sodium glucose co-transporter 2 (SGLT2) inhibitors, which are both approved in the United States and Europe to help control type 2 diabetes alongside diet and exercise. Dapagliflozin and Canagliflozin are the first two sodium glucose co-transporter 2 (SGLT2) inhibitors to be approved in the USA and Europe for use as an adjunct to diet and exercise to fight type 2 diabetes. Study data gleaned demonstrated that SGLT2 inhibition was associated with mild osmotic diuresis, as well weight loss due to less calories taken in participants.
Participants in the aforementioned trial were administered either 300 milligrams of Canagliflozin or 10 milligrams of Dapagliflozin approximately 20 minutes before breakfast each day. At the conclusion of four day treatment periods the participants were assessed for changes in 24 hour urinary glucose excretion and plasma glucose levels. While both Dapagliflozin and Canagliflozin were effective, Canagliflozin was found to offer a greater reduction in the renal threshold for glucose. Dapagliflozin and Canagliflozin were well tolerated by participants, and there were no patients who discontinued the study due to adverse events. The pharmokinetic characteristics of Dapagliflozin and Canagliflozin were determined to be similar in healthy participants.
Dapagliflozin has consistently been found to aid in weight loss as an effective and selective SGLT2 inhibitor, by reducing hyperglycemia in patients with type 2 diabetes and increasing urinary glucose excretion. With more than one-third of adults in the United States considered obese, comorbid conditions like type 2 diabetes are becoming increasingly common. Approximately 80 to 90 percent of people who are diagnosed with type 2 diabetes are also diagnosed as being obese. Being obese disables your body from regulating glucose properly, often leading to complications from type 2 diabetes such as kidney failure. Of the children born in the year 2000 a staggering 1 in every 3 is predicted to be diagnosed with type 2 diabetes in adulthood. These scary statistics make research and development of drugs to fight both type 2 diabetes and obesity crucial. LGM Pharma can assist clients as a supplier/distributor of the APIs Dapagliflozin CAS# 461432-26-8 and Canagliflozin CAS# 842133-18-0 for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.